Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 8/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.31 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.31 |
| ▸ | MERTK | Q12866 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7415517 | 0.84 | DRD2 (0.43) | — | |
| SCHEMBL8562237 | 0.83 | ESR1 (0.39) | ESR1ESR2HDAC6ABHD6 | |
| SCHEMBL8562233 | 0.83 | ESR1 (0.39) | ESR1ESR2HDAC6ABHD6 | |
| SCHEMBL8564898 | 0.82 | ESR1 (0.39) | ESR1ESR2HDAC6ABHD6 | |
| SCHEMBL8564893 | 0.82 | ESR1 (0.39) | ESR1ESR2HDAC6ABHD6 | |
| SCHEMBL7472118 | 0.72 | ESR1 (0.41) | ESR1ESR2HDAC6 | |
| SCHEMBL7472374 | 0.71 | TMEM97 (0.43) | ESR1ESR2 | |
| SCHEMBL7476930 | 0.69 | DRD2 (0.32) | — | |
| SCHEMBL7476926 | 0.69 | DRD2 (0.32) | — | |
| SCHEMBL8562345 | 0.69 | ESR1 (0.39) | ESR1ESR2HDAC6ABHD6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0777667-A1 | CYCLIC BENZAZEPINE UREA DERIVATIVES WITH AGGREGATION-INHIBITING EFFECT | Dr. Karl Thomae GmbH (DE) | 1997-06-11 | — | — | EP | disclosed |
| WO-1996005194-A1 | CYCLIC BENZAZEPINE UREA DERIVATIVES WITH AGGREGATION-INHIBITING EFFECT | DR. KARL THOMAE GMBH (DE) | 1996-02-22 | — | — | WO | disclosed |